363 related articles for article (PubMed ID: 33176972)
1. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
2. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
3.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
4. Synergistic action of combined PARP and ATR inhibition in prostate cancer with ATM loss.
Tregunna R
Nat Rev Urol; 2021 Jan; 18(1):4. PubMed ID: 33262506
[No Abstract] [Full Text] [Related]
5. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
7. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
9. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
[TBL] [Abstract][Full Text] [Related]
10. Germline
Grochot R; Carreira S; Miranda S; Figueiredo I; Bertan C; Rekowski J; Yuan W; Ferreira A; Riisnaes R; Neeb A; Gurel B; de Los Dolores Fenor de la Maza M; Guo C; Carmichael J; Westaby D; Mateo J; Sharp A; McVeigh TP; De Bono J
Eur Urol Open Sci; 2023 Jun; 52():72-78. PubMed ID: 37284046
[TBL] [Abstract][Full Text] [Related]
11. Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.
Sanmartín E; Muñoz L; Piqueras M; Sirerol JA; Berlanga P; Cañete A; Castel V; Font de Mora J
Clin Cancer Res; 2017 Nov; 23(22):6875-6887. PubMed ID: 28830922
[No Abstract] [Full Text] [Related]
12. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
[TBL] [Abstract][Full Text] [Related]
13. Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
Setton JS; Powell SN
Cancer Res; 2020 Jun; 80(11):2085-2086. PubMed ID: 32487588
[TBL] [Abstract][Full Text] [Related]
14. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
15. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
[TBL] [Abstract][Full Text] [Related]
16. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
[TBL] [Abstract][Full Text] [Related]
17. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
18. Genomic and Clinicopathologic Characterization of
Kaur H; Salles DC; Murali S; Hicks JL; Nguyen M; Pritchard CC; De Marzo AM; Lanchbury JS; Trock BJ; Isaacs WB; Timms KM; Antonarakis ES; Lotan TL
Clin Cancer Res; 2020 Sep; 26(18):4869-4881. PubMed ID: 32694154
[TBL] [Abstract][Full Text] [Related]
19. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
[TBL] [Abstract][Full Text] [Related]
20. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
Tsujino T; Takai T; Hinohara K; Gui F; Tsutsumi T; Bai X; Miao C; Feng C; Gui B; Sztupinszki Z; Simoneau A; Xie N; Fazli L; Dong X; Azuma H; Choudhury AD; Mouw KW; Szallasi Z; Zou L; Kibel AS; Jia L
Nat Commun; 2023 Jan; 14(1):252. PubMed ID: 36650183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
